Edwards Lifesciences
Official SEC filings
Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 02:43 UTC.
| Form | Filed | Original document |
|---|---|---|
| 8-K | 2026-11-19 | Read on SEC.gov |
| 10-Q | 2026-11-04 | Read on SEC.gov |
| 8-K | 2026-11-04 | Read on SEC.gov |
| 8-K | 2026-08-28 | Read on SEC.gov |
| 10-Q | 2026-08-04 | Read on SEC.gov |
| 8-K | 2026-07-23 | Read on SEC.gov |
| 8-K | 2026-05-08 | Read on SEC.gov |
| 10-Q | 2026-05-06 | Read on SEC.gov |
SEC annual financial snapshot
Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-22 07:51 UTC.
| Metric | USD | Basis | Period end | Filed | Source |
|---|---|---|---|---|---|
| Revenue | $6.07B | Annual | 2025-12-31 | 2026-02-25 | 10-K |
| Net income | $1.07B | Annual | 2025-12-31 | 2026-02-25 | 10-K |
| Operating cash flow | $1.60B | Annual | 2025-12-31 | 2026-02-25 | 10-K |
| Total assets | $13.70B | As of | 2025-12-31 | 2026-02-25 | 10-K |
| Total liabilities | $3.36B | As of | 2025-12-31 | 2026-02-25 | 10-K |
| Stockholders’ equity | $10.34B | As of | 2025-12-31 | 2026-02-25 | 10-K |
| Cash and cash equivalents | $2.94B | As of | 2025-12-31 | 2026-02-25 | 10-K |
✦ Quant Financial Health how this is computed
- Altman Z-Score is 13.18, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
✦ Quant Revenue Concentration how this is computed
- Transcatheter Aortic Valve Replacement is the largest reported line at 72.38% of revenue, across 3 reported segments.
- The next-largest line, Surgical, is a distant second at 15.41% - a sharp slowdown here would have little to offset it.
Revenue annual, last 8 years
Latest year +11.55% YoY
Margins
- Gross margin
- 78.01%
- Operating margin
- 26.97%
- Net margin
- 17.69%
Key ratios & quality
- Enterprise valuei
- 54.96B
- Altman Z-Scorei
- 13.18
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.72B | 4.35B | 4.39B | 5.23B | 4.46B | 5.01B | 5.44B | 6.07B |
| Gross profit | 2.78B | 3.23B | 3.31B | 3.98B | 3.74B | 4.03B | 4.32B | 4.73B |
| Selling & admin expenses | 1.09B | 1.24B | 1.23B | 1.49B | 1.36B | 1.58B | 1.79B | 2.09B |
| Research & development | 622.20M | 752.70M | 760.70M | 903.10M | 843.60M | 962.90M | 1.05B | 1.08B |
| Operating profit | 1.07B | 1.24B | 1.32B | 1.59B | 1.54B | 1.49B | 1.48B | 1.64B |
| Pretax profit | 761.40M | 1.17B | 916.70M | 1.70B | 1.52B | 1.37B | 1.55B | 1.27B |
| Tax | 39.20M | 119.60M | 93.30M | 198.90M | 195.50M | 152.40M | 152.10M | 216.90M |
| Net profit | 722.20M | 1.05B | 823.40M | 1.50B | 1.52B | 1.40B | 4.17B | 1.07B |
| Basic EPS | 1 | 2 | 1 | 2 | 2 | 2 | 7 | 2 |
| Diluted EPS | 1.13 | 1.64 | 1.30 | 2.38 | 2.44 | 2.30 | 6.97 | 1.83 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 1.53B | 1.55B | 1.57B | 1.65B | 1.74B | 1.72B |
| Gross profit | 1.19B | 1.21B | 1.23B | 1.29B | 1.35B | 1.35B |
| Selling & admin expenses | 502.00M | 514.60M | 602.90M | 522.20M | 561.20M | 560.90M |
| Research & development | 276.20M | 280.70M | 267.70M | 263.30M | 278.90M | 281.40M |
| Operating profit | 430.90M | 425.10M | 370.30M | 514.70M | 519.50M | 517.30M |
| Pretax profit | 400.20M | 348.40M | 90.40M | 459.00M | 519.80M | 363.20M |
| Tax | 64.30M | 56.10M | 26.20M | 78.30M | 278.40M | 61.80M |
| Net profit | 331.50M | 290.30M | 91.20M | 380.70M | 241.40M | 301.40M |
| Basic EPS | 1 | 1 | 0 | 1 | 0 | 1 |
| Diluted EPS | 0.56 | 0.50 | 0.16 | 0.66 | 0.42 | 0.53 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.29B | 2.98B | 3.09B | 3.18B | 3.10B | 4.04B | 6.29B | 6.74B |
| Cash & ST investments | 956.50M | 1.52B | 1.40B | 1.47B | 1.22B | 1.63B | 3.98B | 4.23B |
| Inventory | 607.00M | 640.90M | 802.30M | 726.70M | 875.50M | 903.50M | 1.09B | 1.13B |
| Total assets | 5.32B | 6.49B | 7.24B | 8.50B | 8.29B | 9.36B | 13.06B | 13.70B |
| Total current liabilities | 876.60M | 902.40M | 893.90M | 1.03B | 1.02B | 1.20B | 1.51B | 1.81B |
| Short-term debt | -- | 25.50M | 27.20M | 25.50M | 25.50M | 22.90M | 23.40M | 24.50M |
| Long-term debt | 593.80M | 594.40M | 595.00M | 595.70M | 596.30M | 597.00M | 597.70M | 598.30M |
| Total liabilities | 2,183,300,000.00 | 2,339,800,000.00 | 2,662,800,000.00 | 2,666,700,000.00 | 2,485,800,000.00 | 2,643,800,000.00 | 2,992,400,000.00 | 3,359,600,000.00 |
| Total equity | 3.14B | 4.15B | 4.57B | 5.84B | 5.81B | 6.72B | 10.06B | 10.34B |
| Retained earnings | 2.69B | 3.74B | 4.57B | 6.07B | 7.59B | 8.99B | 13.17B | 14.24B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 6.58B | 6.36B | 6.74B | 6.23B | 6.82B | 7.25B |
| Cash & ST investments | 4.06B | 3.84B | 4.23B | 3.67B | 4.25B | 4.64B |
| Inventory | 1.14B | 1.14B | 1.13B | 1.12B | 1.13B | 1.16B |
| Total assets | 13.49B | 13.27B | 13.70B | 13.32B | 13.87B | 14.14B |
| Total current liabilities | 1.40B | 1.59B | 1.81B | 1.41B | 1.51B | 1.58B |
| Short-term debt | 25.90M | 26.80M | 24.50M | 24.30M | 24.10M | 24.90M |
| Long-term debt | 598.00M | 598.20M | 598.30M | 598.50M | 598.70M | 598.80M |
| Total liabilities | 2,882,200,000.00 | 3,067,200,000.00 | 3,359,600,000.00 | 2,993,700,000.00 | 3,142,200,000.00 | 3,182,900,000.00 |
| Total equity | 10.61B | 10.21B | 10.34B | 10.33B | 10.72B | 10.96B |
| Retained earnings | 13.86B | 14.15B | 14.24B | 14.62B | 14.86B | 15.17B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 926.70M | 1.18B | 1.05B | 1.73B | 1.22B | 895.80M | 542.30M | 1.60B |
| Depreciation & amortization | 77.40M | 89.30M | 107.20M | 134.80M | 139.60M | 144.90M | 155.20M | 156.60M |
| Free cash flow | 685.00M | 904.50M | 647.00M | 1.40B | 953.40M | 629.50M | 259.90M | 1.34B |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -795.50M | -263.30M | -625.40M | -512.80M | -1.73B | -879.60M | -1.16B | -893.40M |
| Ending cash balance | 715.90M | 1.18B | 1.20B | 867.40M | 772.60M | 1.15B | 3.06B | 2.94B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 290.20M | 573.70M | 450.90M | 43.80M | 651.90M | 570.30M |
| Depreciation & amortization | 38.10M | 39.20M | 42.70M | 40.90M | 42.70M | 44.90M |
| Free cash flow | 240.90M | 516.20M | 353.50M | -21.10M | 585.00M | 506.70M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -5.50M | -588.70M | -40.60M | -421.80M | -153.30M | -138.90M |
| Ending cash balance | 3.29B | 2.69B | 2.94B | 2.45B | 2.91B | 3.11B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 23.69 | 28.73 | 18.88 | 28.88 | 26.14 | 22.52 | 50.15 | 10.56 |
| ROA %i | 13.11 | 17.73 | 12.00 | 19.10 | 18.12 | 15.89 | 37.24 | 8.03 |
| ROIC %i | 20.21 | 24.14 | 16.18 | 25.50 | 23.15 | 19.63 | 45.27 | 8.74 |
| 5-year avg ROE %i | 26.27 | 23.34 | 22.89 | 24.22 | 25.26 | 25.03 | 29.31 | 27.65 |
| EBIT margin %i | 21.26 | 27.30 | 21.26 | 32.88 | 33.19 | 26.91 | 28.82 | 21.31 |
| FCF / sales %i | 18.40 | 20.72 | 14.75 | 26.80 | 17.71 | 10.48 | 4.78 | 22.00 |
| Current ratioi | 2.61 | 3.31 | 3.46 | 3.08 | 3.03 | 3.38 | 4.18 | 3.72 |
| Quick ratioi | 1.70 | 2.34 | 2.24 | 2.07 | 1.87 | 2.06 | 3.12 | 2.83 |
| Debt / assetsi | 11.15 | 10.46 | 9.60 | 8.12 | 8.34 | 7.32 | 5.36 | 5.15 |
| LT debt / equityi | 18.91 | 15.75 | 14.60 | 11.39 | 11.47 | 9.96 | 6.77 | 6.59 |
| Interest coveragei | 26.46 | 57.35 | 59.02 | 93.50 | 93.05 | 91.80 | 79.19 | 63.40 |
| Revenue CAGR (3Y) %i | 14.29 | 13.63 | 8.49 | 12.02 | 0.88 | 4.53 | 1.30 | 10.77 |
| Net income CAGR (3Y) %i | 13.43 | 22.50 | 12.16 | 27.68 | 13.28 | 19.42 | 40.56 | -10.98 |
| FCF CAGR (3Y) %i | 15.62 | 22.92 | -7.79 | 26.97 | 1.77 | -0.91 | -42.99 | 11.88 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | 46.10 | 13.85 | 10.56 | 10.72 | 9.50 | 9.70 |
| ROA %i | 35.15 | 10.42 | 8.03 | 8.32 | 7.35 | 7.45 |
| ROIC %i | 41.34 | 11.51 | 8.74 | 10.03 | 7.94 | 8.13 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 29.48 | 29.01 | 21.31 | 22.18 | 22.83 | 23.66 |
| FCF / sales %i | 10.17 | 13.59 | 22.00 | 17.28 | 22.01 | 21.34 |
| Current ratioi | 4.68 | 4.00 | 3.72 | 4.42 | 4.52 | 4.60 |
| Quick ratioi | 3.53 | 2.98 | 2.83 | 3.30 | 3.45 | 3.54 |
| Debt / assetsi | 5.21 | 5.28 | 5.15 | 5.28 | 5.08 | 4.98 |
| LT debt / equityi | 6.42 | 6.60 | 6.59 | 6.57 | 6.41 | 6.26 |
| Interest coveragei | -- | -- | 63.40 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.
Edwards Lifesciences discussion 0 comments